Inflammation and Stroke Risk: A New Target for Prevention
Peter J. Kelly, Robin Lemmens, Georgios Tsivgoulis
Abstract
New therapeutic approaches are required for secondary prevention of residual vascular risk after stroke. Diverse sources of evidence support a causal role for inflammation in the pathogenesis of stroke. Randomized controlled trials of anti-inflammatory agents have reported benefit for secondary prevention in patients with coronary disease. We review the data from observational studies supporting a role for inflammation in pathogenesis of stroke, overview randomized controlled trials of anti-inflammatory therapy in cardiac disease and discuss the potential implications for stroke prevention therapy.
Topics & Concepts
MedicineStroke (engine)PathogenesisInflammationRandomized controlled trialObservational studyDiseaseIntensive care medicineSecondary preventionClinical trialIschemic strokeInternal medicineCoronary heart diseaseBioinformaticsEpidemiologyVascular diseaseResidual riskCardiologyPhysical therapyIschemiaRisk factorNeuroprotectionPrimary preventionCoronary artery diseaseDisease preventionMEDLINENeuroinflammation and Neurodegeneration MechanismsInflammasome and immune disordersAdipokines, Inflammation, and Metabolic Diseases